A seed-stage investor focused on companies with strong growth potential across a range of technology sectors is part of an initiative of its state department of community and economic development. Located in the Eastern US, the organization’s primary mandate is to help develop technologies that will develop new markets and job growth.
The firm is one of the most active seed-stage companies in the country. Since the launch of its seed fund 12 years ago, the firm has invested more than $50 million in over 150 companies that have gone on to raise more than $1.2 billion in follow-on financing. Over recent years, total annual investment in its portfolio has been trending upward, with over $200 million in allocate AUM.
The organization does not have a clearly defined preference for any sector within life sciences, and will make allocations to companies developing therapeutics, diagnostics, medical devices or providing R&D, IT, or regulatory services. It does not discriminate on the basis of indication, but does have a stated interest in orphan indications. Though there is not a specific phase preference for companies developing drugs, most allocations in that area are made to firms developing preclinical stage compounds.
The organization plans to allocate across roughly 15 seed stage life sciences companies over the next several months, in allocation sizes between $250K and $500K.
